Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 25, Art. 11 (pp. 170-185)    |    2024       

»

Primary lymphoma of the central nervous system in patients with hiv

Shnyakin P.G. 1,2, Botov A.V. 1,2, Khorzhevsky V.A. 1, Loseva A.S. 1

1 Federal State Budgetary Educational Institution of Higher Education ?Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky of the Ministry of Health of Russia?, Krasnoyarsk, Russia
2 Regional State Budgetary Health Institution ?Regional Clinical Hospital?, Krasnoyarsk, Russia

Brief summary

The brain is one of the main targets of damage in patients with HIV infection. The virus directly infects brain cells, causing HIV encephalopathy, and at the AIDS stage, opportunistic infections develop. The most common among opportunistic lesions is toxoplasmosis of the brain. Primary CNS lymphoma (PLCNS) occurs in 5-12% of cases. The clinical course, neuroimaging, and prognosis of PLCNS in patients with HIV infection differ from those in immunocompetent patients. The article presents a review of Russian and foreign literature over the past 20 years on the problems of diagnosing and managing patients with HIV-associated PLCNS. Also presented is our own clinical case of a patient with PLCNS on the background of HIV infection, initially, according to neuroimaging data, regarded as malignant glioma.


Key words

primary lymphoma of the central nervous system, HIV infection, AIDS, opportunistic infection

Reference list

1. Ermak T.N. Lokalizaciya ochagov pri toksoplazmoze golovnogo mozga y bolnih VICh-infekciei, Terapevticheskii arhiv 2014; 86(11): 24-28.


2. Horeva M.A. Nevrologicheskie maski VICh-infekcii. Mejdynarodnii naychno-issledovatelskii jyrnal 2018; (1): 65-68.


3. Wright E.J. Neuro OIs: developed and developing countries. Curr Opin HIV AIDS. 2014 Nov;9(6):539-44. doi: 10.1097/COH.0000000000000109.


4. Mihailova N.R. Toksoplazmoz golovnogo mozga y bolnih VICh-infekciei v gorode Orenbyrge. Vestnik Orenbyrgskogo gosydarstvennogo yniversiteta. 2015; (1): 138-144.


5. Graham A.K., Sharma S., Yamamura D. et al. Brain toxoplasmosis and bacterial infection after liver transplantation. Can. J. Neurol. Sci. 2021; 50(1): 155-157. doi: 10.1017/cjn.2021.494


6. Franca R.A. HIV prevalence in primary central nervous system lymphoma: A systematic review and meta-analysis. Pathol Res Pract. 2020;216(11):153-192. doi:10.1016/j.prp.2020.153192. Epub 2020 Sep 6.


7. Drozdov A.A. Sovremennoe sostoyanie problemi differencialnoi diagnostiki stryktyrnih porajenii golovnogo mozga y pacientov so SPIDom po dannim MRT (obzor literatyri). Vestnik Sankt-Peterbyrgskogo yniversiteta. 2018. -T. 13. Vip. 4. - S.403-418.


8. Bayraktar S. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J. Neurooncol. 2011; 101(2):257-65. doi: 10.1007/s11060-010-0252-3. Epub 2010 Jun 6.


9. Gopal S. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013; 105:1221-1229


10. Kiseleva L.M. Variabelnost kliniko-instrymentalnih i laboratornih proyavlenii pervichnoi limfomi golovnogo mozga y VICh-inficirovannih bolnih. Ylyanovskii mediko-biologicheskii jyrnal. ? 4, 2016.- S.27-36.


11. Hairetdinov R.K. Osobennosti diagnostiki i lecheniya VICh-associirovannih nehodjkinskih limfom. Izvestiya Samarskogo naychnogo centra Rossiiskoi akademii nayk. 2014; 16, 5(4): 1344-1350.


12. Dandachi D. Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. Cancer Causes Control. 2019; 30(5):477-488. doi: 10.1007/s10552-019-01144-8. Epub 2019 Mar 19.


13. Chen J. Clinical pathology of primary central nervous system lymphoma in HIV-positive patients-a 41 Chinese patients retrospective study. Ann Diagn Pathol. 2023; 63:152108. doi: 10.1016/j.anndiagpath.2023.152108. Epub 2023 Jan 7.


14. Gybkin A.V. Pervichnie limfoproliferativnie zabolevaniya centralnoi nervnoi sistemi. Klinicheskaya onkogematologiya. 2008; 1(4): 323-332.


15. Pyzireva L.V. Infekcii, vizvannie virysom Epshteina-Barra, y VICh-inficirovannih pacientov. Jyrnal mikrobiologii, epidemiologii i immynobiologii. 2016; 6: 108-116.


16. Volkova L.I. Slojnosti diagnostiki pervichnoi limfomi golovnogo mozga (klinicheskii slychai). Annali klinicheskoi i eksperimentalnoi nevrologii. 2017; 11 (3): 47-52.


17. Gandhi M.K. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood. 2021; 137(11):1468-1477. doi:10.1182/blood.2020008520.


18. Dydina G.A. VICh-associirovannie limfomi. Kreativnaya hiryrgiya i onkologiya. 2022; 12(4):320-327. https://doi.org/10.24060/2076-3093-2022-12-4-320-327.


19. Brandsma D. Primary CNS lymphoma in HIV infection. Handb Clin Neurol. 2018; 152:177-186. doi: 10.1016/B978-0-444-63849-6.00014-1.


20. Marretta L. Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients. Eur J Med Res. 2011; 16:197-205.


21. Sakai M. MRI imaging features of HIV-related central nervous system diseases: diagnosis by pattern recognition in daily. Jpn J Radiol. 2021; 39(11):1023-1038. doi: 10.1007/s11604-021-01150-4. Epub 2021 Jun 14.


22. Harjani R.G. Intracranial lymphoma in human immunodeficiency virus-infected patients: A diagnostic dilemma? Indian J Sex Transm Dis AIDS. 2022; 43(1):82-84. doi: 10.4103/ijstd.ijstd_10_21. Epub 2022 Jun 7.


23. Javadi S. HIV-related malignancies and mimics: imaging findings and management. Radiographics. 2018; 38:2051-2068.


24. Westwood T.D. Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients. Eur J Radiol. 2013;82(8):374-379. doi: 10.1016/j.ejrad.2013.03.008. Epub 2013 Apr 8.


25. Marcus C. Imaging in differentiating cerebral toxoplasmosis and primary CNS lymphoma with special focus on FDG PET/CT. AJR Am J Roentgenol. 2020; 216:157-164.


26. González-Aguilar A. The management of primary central nervous system lymphoma related to AIDS in the HAART era. Curr Opin Oncol. 2011;23(6):648-53. doi: 10.1097/CCO.0b013e32834b6adc.


27. Newell M.E. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004 15; 100(12):2627-2636. doi: 10.1002/cncr.20300.


28. Gijs P.-J. Long-term remission of AIDS-related primary central nervous system lymphoma in a patient under antiretroviral therapy: a case report and review of the literature. AIDS Res Ther. 2021; 18(1):76. doi: 10.1186/s12981-021-00403-6.


29. Aboulafia D.M. Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS. 2007;21(12):900-7. doi: 10.1089/apc.2007.0009.


30. Holte H. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/ follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013;24(5):1385-1392. https://doi.org/10.1093/annonc/mds621


31. Gupta N.K. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017;19(1):99-108. https://doi.org/10.1093/neuonc/now155


32. Wang Z. Incidence and spectrum of infections among HIV/AIDS patients with lymphoma during chemotherapy. J Infect Chemother. 2021;27(10):1459-1464. https://doi.org/10.1016/j.jiac.2021.06.012.


33. Shmidt A.R., Kyrtasova L.M., Shylmin A.V.


Himioprofilaktika vertikalnoi peredachi VICh-infekcii v Krasnoyarskom krae. Sibirskoe medicinskoe obozrenie. 2015;1: 90-94. DOI:10.20333/25000136-2015-1-90